BioCentury | Mar 27, 2021
Product Development

A Vir’s-eye view of the path forward for its COVID mAbs

...ability to recruit NK cells and macrophages to kill infected cells. Because ACTIV-3 tested VIR-7831 head-to-head with a mAb cocktail from Brii Biosciences...
BioCentury | Mar 26, 2021
Finance

March 25 Quick Takes: Lava flows down on first day after $100.5M IPO; plus Scipher, Eliem, Brii, Bioheng, RiverVest, JSR Life Science and Apnimed

...investors are going earlier and earlier, Singapore’s GIC and Lake Bleu Capital have invested in Brii Biosciences’...
BioCentury | Mar 5, 2021
Product Development

March 4 COVID Quick Takes: More guidance on vaccines for variants; plus EMA begins review of Sputnik V, Novartis-CureVac, Bharat-Ocugen, Novavax and more

...cascade.TARGETSTNFSF14 (LIGHT; CD258) – Tumor necrosis factor (TNF) ligand superfamily member 14 Danielle Golovin NVX-CoV2373 Covaxin (BBV152) CVnCoV Sputnik V (Gam-COVID-Vac) APL-9 Brii Biosciences Novavax...
BioCentury | Mar 4, 2021
Product Development

COVID-19 mAbs work best early: Data Byte

...of ACTIV-3 testing a mAb cocktail from Brii Biosciences...
BioCentury | Feb 13, 2021
Product Development

ACTIV-2 looks beyond mAb infusions with four new treatment arms

...combination study of mAbs BRII-196 and BRII-198 from Brii Biosciences...
...Pharmaceutical Co. Ltd. Eli Lilly and Co. AbCellera Biologics Inc. Brii Biosciences Transmembrane...
BioCentury | Jan 22, 2021
Emerging Company Profile

SciNeuro reunites GSK R&D vets to bring CNS therapies to China

...LLC, Inovio Pharmaceuticals Inc. (NASDAQ:INO) and Adaptimmune Therapeutics plc (NASDAQ:ADAP).In 2019, cross-border infectious disease company Brii Biosciences...
BioCentury | Dec 19, 2020
Politics, Policy & Law

COVID-19 mAb developers with ties to China excluded from Warp Speed

...could treat or prevent COVID-19. Two biotechs focused on infectious diseases, Vir Biotechnology Inc. (NASDAQ:VIR) and Brii Biosciences...
...decades devoted myself to public health, it was very disappointing to recognize the new reality.” Steve Usdin Brii Biosciences Regeneron...
BioCentury | Dec 19, 2020
Product Development

Why Vir, Brii believe their mAbs may succeed where others have failed

...combines BRII-196 and BRII-198, two mAbs from Brii Biosciences.Vir...
...begin in early 2021, the company said. Steve Usdin Brii Biosciences Regeneron...
BioCentury | Dec 19, 2020
Product Development

Features that differentiate four leading COVID mAbs: Data Byte

...the candidate’s Fc domain to boost the half-life and promote immune effector activity against infected cells.Brii Biosciences...
...Fc receptorFCGR – Fc ɣ receptor Sandi Wong casirivimab/imdevimab (REGN-COV2, REGN-COVID19, REGN10933/REGN10987) etesevimab (LY-CoV016, JS016) BRII-196 BRII-198 VIR-7831 (GSK4182136) Eli Lilly and Co. Brii Biosciences Regeneron...
BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

...Rock was most recently clinical project leader and VP of clinical research at MacroGenics Inc. (NASDAQ:MGNX). Brii Biosciences...
...and CEO of Meditope Biosciences Inc. BC Staff Thrive Earlier Detection Corp. Black Diamond Therapeutics Inc. MorphoSys AG Partner Therapeutics Inc. Brii Biosciences Deep...
Items per page:
1 - 10 of 32
BioCentury | Mar 27, 2021
Product Development

A Vir’s-eye view of the path forward for its COVID mAbs

...ability to recruit NK cells and macrophages to kill infected cells. Because ACTIV-3 tested VIR-7831 head-to-head with a mAb cocktail from Brii Biosciences...
BioCentury | Mar 26, 2021
Finance

March 25 Quick Takes: Lava flows down on first day after $100.5M IPO; plus Scipher, Eliem, Brii, Bioheng, RiverVest, JSR Life Science and Apnimed

...investors are going earlier and earlier, Singapore’s GIC and Lake Bleu Capital have invested in Brii Biosciences’...
BioCentury | Mar 5, 2021
Product Development

March 4 COVID Quick Takes: More guidance on vaccines for variants; plus EMA begins review of Sputnik V, Novartis-CureVac, Bharat-Ocugen, Novavax and more

...cascade.TARGETSTNFSF14 (LIGHT; CD258) – Tumor necrosis factor (TNF) ligand superfamily member 14 Danielle Golovin NVX-CoV2373 Covaxin (BBV152) CVnCoV Sputnik V (Gam-COVID-Vac) APL-9 Brii Biosciences Novavax...
BioCentury | Mar 4, 2021
Product Development

COVID-19 mAbs work best early: Data Byte

...of ACTIV-3 testing a mAb cocktail from Brii Biosciences...
BioCentury | Feb 13, 2021
Product Development

ACTIV-2 looks beyond mAb infusions with four new treatment arms

...combination study of mAbs BRII-196 and BRII-198 from Brii Biosciences...
...Pharmaceutical Co. Ltd. Eli Lilly and Co. AbCellera Biologics Inc. Brii Biosciences Transmembrane...
BioCentury | Jan 22, 2021
Emerging Company Profile

SciNeuro reunites GSK R&D vets to bring CNS therapies to China

...LLC, Inovio Pharmaceuticals Inc. (NASDAQ:INO) and Adaptimmune Therapeutics plc (NASDAQ:ADAP).In 2019, cross-border infectious disease company Brii Biosciences...
BioCentury | Dec 19, 2020
Politics, Policy & Law

COVID-19 mAb developers with ties to China excluded from Warp Speed

...could treat or prevent COVID-19. Two biotechs focused on infectious diseases, Vir Biotechnology Inc. (NASDAQ:VIR) and Brii Biosciences...
...decades devoted myself to public health, it was very disappointing to recognize the new reality.” Steve Usdin Brii Biosciences Regeneron...
BioCentury | Dec 19, 2020
Product Development

Why Vir, Brii believe their mAbs may succeed where others have failed

...combines BRII-196 and BRII-198, two mAbs from Brii Biosciences.Vir...
...begin in early 2021, the company said. Steve Usdin Brii Biosciences Regeneron...
BioCentury | Dec 19, 2020
Product Development

Features that differentiate four leading COVID mAbs: Data Byte

...the candidate’s Fc domain to boost the half-life and promote immune effector activity against infected cells.Brii Biosciences...
...Fc receptorFCGR – Fc ɣ receptor Sandi Wong casirivimab/imdevimab (REGN-COV2, REGN-COVID19, REGN10933/REGN10987) etesevimab (LY-CoV016, JS016) BRII-196 BRII-198 VIR-7831 (GSK4182136) Eli Lilly and Co. Brii Biosciences Regeneron...
BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

...Rock was most recently clinical project leader and VP of clinical research at MacroGenics Inc. (NASDAQ:MGNX). Brii Biosciences...
...and CEO of Meditope Biosciences Inc. BC Staff Thrive Earlier Detection Corp. Black Diamond Therapeutics Inc. MorphoSys AG Partner Therapeutics Inc. Brii Biosciences Deep...
Items per page:
1 - 10 of 32